NASH Experts Webcasts
Impacting NASH: Focus on Liver and Cardiovascular Benefits
Epidemiology of NASH: CV- and Liver-related Outcomes
- Professor and Chairman, Department of Medicine, Inova Fairfax Hospital
- President, Inova Medicine and Chairman, Clinical Research’ Inova Health System, Falls Church, Virginia
Dr Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry (Alpha Omega Alpha 1989) in Rochester, NY. He completed his residency in internal medicine with a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California, while earning his master of public health degree from San Diego State University School of Public Health, San Diego, California. He served as Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio, before establishing the Canter for Liver Diseases at Inova Fairfax Hospital, which is now renowned for research related to non-alcoholic fatty liver disease (NAFLD) and outcomes research in liver disease. He has served as Vice President of Research for Inova Health System and currently serves as the President and Chairman of the Board of Trustees of the Chronic Liver Disease Foundation and Member and Vice Chairman of the Board of Inova Health System Foundation.
Dr Younossi pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes (PROs), economic assessment and other areas of outcomes research in liver disease. He leads a number of international efforts related to NAFLD and PROs in liver disease though global collaborations, including the Chair of Global NASH Council and the Global Liver and NASH Registries. In addition to research and administrative duties, Dr Younossi has been actively involved in teaching students, residents and fellows. He has also served as Chair, Director or faculty of a number international scientific and CME related courses.
Dr Younossi specializes in hepatology and gastroenterology and has authored over 510 articles, 3 books, 6 journal supplements, over 25 book chapters, over 780 abstracts at the international scientific meetings and over 415 faculty lectures. His academic productivity has led to an H-index of 81. Dr Younossi also serves as the Associate Editor of J of Hepatology and previously served as the co-editor of Liver International, and on the editorial board of a number of important medical journals.
Resmetirom for the Treatment of NASH
- Visiting Professor of Hepatology, Radcliffe Department of Medicine, University of Oxford
- Medical Director, Pinnacle Clinical Research, San Antonio, Texas
Dr Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He is board certified in both Internal Medicine and Gastroenterology.
Dr Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Currently, Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research.
Real-life Treatment of NASH: Non-invasive Imaging in NASH Diagnosis and Treatment. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to Predict Benefit in Patients with NASH: Focus on Resmetirom
- Director NAFLD Research Center
- Director of Hepatology
- Professor of Medicine
- Vice Chief Division of Gastroenterology
- University of California at San Diego San Diego, California
Dr Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic steatohepatitis (NASH), and non-invasive assessment of NAFLD using advanced imaging modalities.
Dr Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications such as establishment of MRI-PDFF as a non-invasive biomarker of treatment response in early phase trials in NASH, which has now been adopted in more than 25 clinical trials conducted worldwide. He holds two patents on non-invasive biomarkers of NAFLD and fibrosis.
His research is funded by the National Institutes of Health including R01, U01, P30 and P01 grant mechanisms, Foundation of NIH, National Science Foundation as well as several investigator initiated research projects funded by the industry. He is the Principal Investigator, UCSD, for the NIDDK-sponsored NASH Clinical Research Network. He served as the elected Chair of the NAFLD, Special Interest Group of the American Association for the Study of Liver Diseases. And is the elected member to the National Board of Directors of the American Liver Foundation.
He serves on the Editorial Board of Gastroenterology, Journal of Hepatology, GUT and Nature Reviews in Gastroenterology and Hepatology. He is the Deputy Editor of HEPATOLOGY, the official journal of the AASLD.
Dr Loomba has published more than 250 manuscripts and has an H-index of 75. He is among the top 1% of the globally highly cited scientists across all fields in 2019 by Web of Science. He is an elected member of American Society of Clinical Investigation.
The Intersection of CVD and NASH, the Next CVD Prevention Frontier
- Immediate Past-President, American Society for Preventive Cardiology
- Excel Medical Clinical Trials, LLC, Founder, Chief Medical Officer
- Clinical Affiliate Professor of Biomedical Science
- Department of Integrated Medical Sciences, Florida Atlantic University
- Charles E. Schmidt College of Medicine
- Medical Director, Women’s Preventive Cardiology
- Christine E. Lynn Women’s Health & Wellness Institute
- Boca Raton Regional Hospital Boca Raton, Florida
Dr Seth J. Baum, a graduate of Columbia College and Columbia College of Physicians and Surgeons, completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology. He has directed and founded multiple Cardiac Catheterization and Electrophysiology laboratories. Dr Baum has worked extensively in Integrative Cardiology, directing the Boca Raton division of Harvard’s Mind/Body Medicine Institute.
Dr Baum is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. He is a Founding Physician/Scientist Member of the Society for Cardiovascular CT and is board certified in Cardiovascular CT. Dr Baum served as treasurer of the International Society for the Study of Fatty Acids and Lipids. He founded and directs the Women’s Preventive Cardiology program at Boca Raton Regional Hospital. He is the President of the American Society for Preventive Cardiology (ASPC). Annually, Dr Baum chairs the ASPC’s Conference on CVD Prevention. Dr Baum is the Secretary/Treasurer of the Board of Directors of the FH Foundation. He sits on the American Heart Association’s Council for Epidemiology and Prevention as well as its Leadership committee, the Interdisciplinary Council for Prevention, and the Prevention Science Committee. He has written numerous peer reviewed papers as well as two books, The Total Guide to a Healthy Heart, and Age Strong, Live Long; Lessons from my Patients. In 2013 he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. Dr Baum is the Founder and Chief Medical Officer of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials.